Inovio Pharmaceuticals has announced that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a ...
Tags: DNA Vaccine, MERS Virus
Inovio Pharmaceuticals has received a US patent covering SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV). The patent covers Inovio's synthetic consensus HPV antigens, DNA constructs and vaccines ...
Tags: Inovio Pharmaceuticals, SynCon vaccine, HPV
Inovio Pharmaceuticals has reported a net loss attributable to the company of $6.62m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss attributable to the company of $4.54m, or $0.04 per share, for ...
Tags: Inovio Pharmaceuticals, Loss Increases, loss attributable